There are currently 48 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Amyotrophic Lateral Sclerosis participants are California, Florida, Pennsylvania and New York.
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
NCT04057898
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/19/2024
Locations: University of California, Orange, California +16 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Analysis of Human ALS Tissues and Registry of ALS Patients
NCT05067179
Recruiting
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a n... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/18/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
NCT05189106
Recruiting
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers of an ALS-related gene, such as a hexanucleotide expansion in the C9ORF72 gene, with evidence of abnormal inflammatory signaling in cerebrospinal fluid (CSF) at baseline. Each participant will be treated with baricitinib for 24 weeks; no placebo will be given. Participan... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/17/2024
Locations: Massachusetts General Hospital - ALS Site, Boston, Massachusetts +1 locations
Conditions: Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT03225144
Recruiting
Background: Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors. Objective: To test people with movement or thinking and memory problems to see if they are eligible for research studies. Eligibility: People ages 18 and older with a neurodegenerative disorder associated with accumulation of TDP-43 or Tau proteins Design:... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Progressive Supranuclear Palsy, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Register for Updates
Precise Robotically IMplanted Brain-Computer InterfacE
NCT06429735
Recruiting
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
06/11/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Quadriplegia/Tetraplegia, Tetraplegic; Paralysis
Register for Updates
Study of SPG302 in Healthy Volunteers and ALS Participants
NCT05882695
Recruiting
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/05/2024
Locations: Mass General Brigham, Boston, Massachusetts +4 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972
Recruiting
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Gender:
All
Ages:
10 years and above
Trial Updated:
05/30/2024
Locations: University of California San Diego, La Jolla, California +21 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Study of Safety and of the Mechanism of BLZ945 in ALS Patients
NCT04066244
Recruiting
It is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of California-San Diego ., La Jolla, California +9 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Clinical Procedures to Support Research in ALS
NCT03489278
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: University of California, Irvine, Irvine, California +10 locations
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Register for Updates
Spinal Cord Associative Plasticity for ALS
NCT06172621
Recruiting
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen weakened nerve circuits between the brain and hand muscles in people with ALS. The current proposal will take the next step of individualizing this intervention, then applying it repetitively in an attempt to achieve direct clinical benefit on hand strength and functio... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/22/2024
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Neurologic Stem Cell Treatment Study
NCT02795052
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: MD Stem Cells, Westport, Connecticut +2 locations
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Register for Updates
NYSCF Scientific Discovery Biobank
NCT06203106
Recruiting
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.
Gender:
All
Ages:
30 days and above
Trial Updated:
03/21/2024
Locations: New York Stem Cell Foundation Research Institute, New York, New York
Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Register for Updates